Biotech entity
Sentiment skews more negative than the wider beat, at 57% negative against 19% across all 413 Biotech stories in the same window. Of the tracked stories, 3 of 7 also mention Bundibugyo virus, the most common co-covered peer. That works out to roughly 0.4 stories per week across a 131-day span. The busiest single day carried 2.
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 43 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Sentiment skews more negative than the wider beat, at 57% negative against 19% across all 413 Biotech stories in the same window. Of the tracked stories, 3 of 7 also mention Bundibugyo virus, the most common co-covered peer. That works out to roughly 0.4 stories per week across a 131-day span. The busiest single day carried 2. They are less corroborated than the beat average, carrying 2.9 original sources each against 3.6 for the same window. At 7.1, the average consequence score sits above the same-window beat average of 6.2. clinical-trial accounts for 3 of the 7 tracked stories, while 2 other categories carry the remainder. This profile follows 7 Biotech stories mentioning World Health Organization across the period from March 4, 2026 to July 12, 2026.
Computed from the 7 stories linked to this entity, with beat comparisons drawn from all 413 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering World Health Organization. Shared-story counts are live from our verified record — not editorial picks.
Elimination Target
Deadline for reaching the 90-70-90 vaccination, screening, and treatment goals.
US aid worker tests positive
CDC confirms a US citizen aid worker in Congo has Ebola; contact tracing and containment measures initiated.
Record outbreak confirmed
Africa CDC reports 1,830 confirmed cases and 648 deaths, marking the fastest-growing Ebola outbreak ever recorded on the continent.
Clinical trials for Ebola treatment begin
Researchers launch a highly anticipated study to test experimental therapies against the Bundibugyo strain.
Kenya Ebola facility suspended
A Kenyan court orders suspension of construction on a US-backed isolation facility for exposed Americans, pausing Trump administration plans.
First US doctor infected
An American doctor working in Congo tests positive during outbreak's first week and is transferred to Germany for treatment.
Congo declares fresh Ebola outbreak
Authorities announce outbreak of Bundibugyo virus after weeks of undetected transmission, according to WHO.
$5.1M Grant Awarded
Major funding secured to scale screening and vaccination across the region.
Pilot Programs
Initial HPV self-collection pilots begin in select Pacific island nations.
WHO Global Strategy
WHO launches the global strategy to accelerate the elimination of cervical cancer.
75 healthcare workers infected with the Ebola Bundibugyo strain in DRC expose critical gaps in vaccine coverage and trial infrastructure, pressuring biopharma to accelerate strain-specific countermeasures.
Source: yahoo.com · medscape.com
The Congo Ebola outbreak driven by the rare Bundibugyo virus has ballooned to 1,830 cases with zero approved vaccines or treatments, forcing an urgent launch of clinical trials. For biotech and pharma, this emergency opens a race to develop broad-spectrum filovirus countermeasures.
With no approved therapies for the Bundibugyo Ebola strain and an outbreak surpassing 500 fatalities, two candidate drugs have begun a clinical trial, and a prophylactic agent trial is imminent. The collaborative effort signals a pivot toward rapid, integrated R&D for neglected filoviruses.
At least 30 deaths with Ebola symptoms in a crowded DRC camp highlight untreated spread and demand for rapid point-of-care diagnostics and expanded vaccine access. With 5 million displaced at risk, biopharma firms face calls to accelerate countermeasure deployment.
Source: tribune.com.pk · examiner.com.au
The rare Bundibugyo Ebola virus has infected 782 people and killed 181 in Congo, with a record 72 new cases in one day. No approved vaccine or treatment exists for this strain, creating an urgent gap for biotech and pharma to address with rapid countermeasure development.
A new $5.1 million grant has been awarded to accelerate cervical cancer elimination efforts across the Pacific region, focusing on HPV vaccination and advanced screening. The initiative aligns with the WHO's global strategy to eradicate the disease through the 90-70-90 targets by 2030.
The CDC has issued urgent travel advisories for several popular tourist destinations following a confirmed spread of poliovirus. This development signals a significant setback for global eradication efforts and is expected to drive a surge in demand for inactivated poliovirus vaccines (IPV).
World Health Organization is linked from 7 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
